Atrix Laboratories' CEO David Bethune talks to The Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--Oct. 24, 2000 The Wall Street Transcript A generic term for any kind of copy, particularly an official or certified representation of the record of what took place in a court during a trial or other legal proceeding. A transcript of record has published an in-depth interview with David Bethune, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Atrix Laboratories (Nasdaq:ATRX ATRX Alpha-Thalassemia/Mental Retardation Syndrome, Nondeletion Type, X-Linked ), in which he talks at length about the company's future. The entire 3,300-word interview is available free online at http://www.twst.com/ceos.htm Bethune gives an overview of the company. "Atrix Laboratories has been in existence for about 12 years and it started out primarily as a dental company. We have successfully developed two pharmaceutical dental products, three dental devices, and three over-the-counter products, two of which are specific for oral applications. However, it became clear that in order for Atrix to become a successful growth-oriented company, we needed a broader focus." Bethune explains, "In the last year, Atrix has made a dramatic shift to capitalize on Cap´i`tal`ize on` v. t. 1. To turn (an opportunity) to one's advantage; to take advantage of (a situation); to profit from; as, to capitalize on an opponent's mistakes s>. our strength in drug delivery by proving that Atrigel(R), our flagship technology -- which we already had proven was safe and effective for local delivery of a drug in the case of our prescription dental product, Atridox(R) -- was safe and effective for systemic systemic /sys·tem·ic/ (sis-tem´ik) pertaining to or affecting the body as a whole. sys·tem·ic adj. 1. Of or relating to a system. 2. delivery of drug. That totally changed Atrix's focus from a dental company to a drug delivery and drug development company." Looking forward, Bethune states, "Atrix has great potential for sustained growth as we go forward. We have five patented platform technologies. We have a strong, opportunistic opportunistic /op·por·tu·nis·tic/ (op?er-tldbomacn-is´tik) 1. denoting a microorganism which does not ordinarily cause disease but becomes pathogenic under certain circumstances. 2. pipeline. We have marketed products, which bring in revenue. Atridox for example, our product for periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where , is on the market now in the US, and it is being introduced in Europe in the coming months. We have a wonderful opportunity to make additional money by selling this product through distributors and through our licensing candidates in Europe and throughout the world." This interview is part of a 166-page Specialty Pharmaceuticals, Generics & Drug Delivery Companies Issue available at http://www.twst.com/info/info190.htm or by calling (212) 952-7433 The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors Long-term investor A person who makes investments for a period of at least five years in order to finance his or her long-term goals. for over 37 years. The Wall Street Transcript has launched a new free service where investors can ask Atrix Laboratories (or any public company) a question at http://www.qawire.com The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call (800) 246-7673. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion